Designing Marketing Strategies Best Practices
Best Practices, LLC has conducted extensive research in the field of Designing Marketing Strategies. Browse through and sample our published Designing Marketing Strategies research in the topics below:
| |  | Lifecycle Management Excellence: Mature Brand Organizations and High-Performing Strategies  
Non-members: Click here to review a complimentary excerpt from "Lifecycle Management Excellence: Mature Brand Organizations and High-Performing Strategies"
STUDY OVERVIEW
Increasing cost pressures are forcing pharmaceutical companies to explore sources of revenue beyond the development of new drugs. In this time- and cost-constrained environment, companies have had begun to look at lifecycle management strategies with newfound interest.
To help biopharma companies more effectively conduct the many activities related to lifecycle management, Best Practices, LLC conducted a study to provide important benchmarks on the optimal size and structure of Mature Brand Organizations. In addition, this study provides pharmaceutical and biotech executives with important benchmarks on recent barriers and regulations affecting the industry as well as the lifecycle strategies used by Mature Brand Organizations or the groups responsible for lifecycle management.
This study identifies and documents current practices and trends at Mature Brand Organizations and explores the rationale for different tactical approaches for lifecycle management strategies. In addition, the research provides insights into which strategies will survive in a changing pharmaceutical environment.
KEY TOPICS
Barriers of Key LCM Strategies
Strategies Weakened by Regulation or Reform
Mature Brand Organizations
Case Example of Pfizer's Lipitor
Other Success Factors and Lessons Learned
KEY METRICS
Technical Feasibility of Lifecycle Management Strategies Growing Mature Product
Regulatory Feasibility of Lifecycle Management Strategies Growing Mature Product
Cost of Lifecycle Management Strategies Growing Mature Product
Strategies Weakened by Regulation/Reform in the next 12-24 months
Length of time since Mature Brand Organization establishment
Number of products MBO currently manages
Responsibilities of Mature Brand Organization
Regions supported by Mature Brand Organization
Key factors governing "mature brand" status
Major expenses of MBO Budget
SAMPLE KEY FINDINGS
Global Reach: Nearly 40% of the dedicated Mature Brand groups represented in this study are focused only on the U.S. market. The remainder of groups have additional responsibility in other countries: 62% are responsible for emerging markets, and some 40% claim responsibility countries outside developed or emerging markets (i.e., “Rest of World”).
Emerging Markets Least Impacted: Extending into emerging markets will be the LCM strategy least impacted by regulation/reform over the next 12-24 months.
METHODOLOGY
Research participants included 25 executives and managers from 18 different pharmaceutical and biotech companies. Respondents represented more than a dozen therapeutic areas.
Lifecycle Management Excellence: Effectiveness and ROI of Lifecycle Strategies
Non-members: Click here to review a complimentary excerpt from "Lifecycle Management Excellence: Effectiveness and ROI of Lifecycle Strategies"
STUDY OVERVIEW
With fewer products in the pipeline and more at the edge of the patent cliff, strategies to extend the commercial life of mature brands are critical to the bio-pharmaceutical industry today. Used correctly, strategies can add as many as 10 years and billions of dollars to the life of an established or mature brand. This study is designed to help brand and marketing leaders identify winning lifecycle management (LCM) strategies they can use to extend the commercial life of bio-pharmaceutical products. The study examines ROI, effectiveness, time and costs required for over 20 different LCM strategies.
To help pharmaceutical and biotech companies more effectively overcome the many challenges related to lifecycle management as patents expire and pipelines thin, Best Practices, LLC conducted a study to provide important benchmarks to determine the value of different lifecycle management strategies. Specifically, this benchmark study provides executives with important metrics on successful strategies in the current pharmacentical environment and the returns they can anticipate from these different tactics.
KEY TOPICS
Corporate Lifecycle Management (LCM) Goals & Policies
Use of Key LCM Strategies
Comparative Effectiveness of Key LCM Strategies
Relative Costs of Key LCM Strategies
Relative Time of Key LCM Strategies
ROI of Key LCM Strategies
Key Strategy Profiles
Gains from Using LCM Strategies
KEY METRICS
Key Lifecycle Management Goals for Mature Brands
Targeting of Physicians in Support of Mature Brands
Late-Life Strategies Used on Behalf of Mature Brands
Usage of 20+ LCM Strategies
Effectiveness of LCM Strategies
Cost of LCM Strategies
Return on Investment of LCM Strategies
Time Required for LCM Strategies
Number of Months LCM Strategies are Employed
Incremental Sales Gained by LCM Strategies
SAMPLE KEY FINDINGS
Litigation Has Highest ROI: Overall, litigation strategies achieved the highest ROI for participants, with 40% realizing more than 100% ROI and another 20% realizing over 50%. Fixed dose combination, one of the more expensive strategies, had the second highest ROI rating. With respect to time and costs, branded/authorized generics was the most effective strategy in garnering a high ROI.
Financial Gain: Financial gain from using individual strategies among the benchmark class ranged from $0 to $10 billion, with a median gain of $30 million. The average gain was $254 million.
METHODOLOGY
Research participants included 25 executives and managers from 18 different pharmaceutical and biotech companies. Respondents represented more than a dozen therapeutic areas.
|
|